CoChat

Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: a prospective observational cohort study

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 21 of the 45 sources its claims cite were checked for support.

Abstract

Background: Severe coronavirus disease 2019 (COVID-19) is frequently associated with hyperinflammation and hyperferritinemia. The latter is related to increased mortality in COVID-19. Still, it is not clear if iron dysmetabolism is mechanistically linked to COVID-19 pathobiology. Methods: We herein present data from the ongoing prospective, multicentre, observational CovILD cohort study (ClinicalTrials.gov number, NCT04416100), which systematically follows up patients after COVID-19. 109 participants were evaluated 60 days after onset of first COVID-19 symptoms including clinical examination, chest computed tomography and laboratory testing. Results: We investigated subjects with mild to critical COVID-19, of which the majority received hospital treatment. 60 days after disease onset, 30% of subjects still presented with iron deficiency and 9% had anemia, mostly categorized as anemia of inflammation. Anemic patients had increased levels of inflammation markers such as interleukin-6 and C-reactive protein and survived a more severe course of COVID-19. Hyperferritinemia was still present in 38% of all individuals and was more frequent in subjects with preceding severe or critical COVID-19. Analysis of the mRNA expression of peripheral blood mononuclear cells demonstrated a correlation of increased ferritin and cytokine mRNA expression in these patients. Finally, persisting hyperferritinemia was significantly associated with severe lung pathologies in computed tomography scans and a decreased performance status as compared to patients without hyperferritinemia. Discussion: Alterations of iron homeostasis can persist for at least two months after the onset of COVID-19 and are closely associated with non-resolving lung pathologies and impaired physical performance. Determination of serum iron parameters may thus be a easy to access measure to monitor the resolution of COVID-19. Trial registration: ClinicalTrials.gov number: NCT04416100.

Overview

CoChat Summary

TL;DR

In a prospective observational cohort, 109 COVID-19 survivors evaluated about 60 days after symptom onset showed persistent iron dysmetabolism, including iron deficiency in 30%, anemia in 9%, and hyperferritinemia in 38%. Persisting hyperferritinemia was associated with more severe lung pathology on CT and reduced six-minute walking distance.

Key findings

  • At 60 days, 30% had iron deficiency (13% absolute, 17% functional), 9.2% had anemia, and 38% had hyperferritinemia; hyperferritinemia was more frequent in males (48%) than females (23%, p = 0.009).
  • Anemia was more common after severe/critical COVID-19: 90% of anemic patients had previously had severe to critical disease, and anemic patients had higher IL6 (p = 0.009) and CRP (p = 0.031).
  • Hyperferritinemia correlated with serum hepcidin but not with CRP or IL6; hepcidin was positively correlated with TSAT (ρ = 0.328, p < 0.01) and negatively with sTFRF index (ρ = −0.439, p < 0.01).
  • Patients with persisting hyperferritinemia had more frequent and severe pathological CT findings and, in a subgroup of 23 tested, decreased six-minute walking distance compared with those with normal ferritin.

Methods

  • Prospective, multicentre, observational CovILD cohort study (NCT04416100); 109 adults aged ≥18 years with prior mild to critical COVID-19 were evaluated 60 days (SD ± 12) after first symptom onset.
  • Assessments included clinical examination, structured symptom questionnaire, performance evaluation including six-minute walking test, blood sampling, and low-dose chest CT scored for lung pathology severity (0–25).
  • Iron parameters, anemia definitions, hyperferritinemia cut-offs, PBMC mRNA expression by RT-PCR, and group comparisons/correlations were analyzed with nonparametric tests and Sidak adjustment where appropriate.

Limitations

  • The authors state the data are observational and do not provide evidence for causality; further mechanistic evaluation is warranted.
  • Evident from the text: follow-up is a single post-acute time point around 60 days, so persistence beyond that window is not established.
  • Evident from the text: the six-minute walking test analysis was limited to a subgroup of 23 participants (12 with hyperferritinemia, 11 without).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12931-020-01546-2

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Serum markers of iron homeostasis in post-acute COVID-19 according to disease severity. Correlations of a hepcidin-25, b soluble transferrin receptor (sTFR), c C-reactive protein (CRP) and d interleukin-6 (IL6) with serum ferritin are shown. ρ indicates the correlation coefficient as calculated with Spearman-rank test
Fig. 1 Serum markers of iron homeostasis in post-acute COVID-19 according to disease severity. Correlations of a hepcidin-25, b soluble transferrin receptor (sTFR), c C-reactive protein (CRP) and d interleukin-6 (IL6) with serum ferritin are shown. ρ indicates the correlation coefficient as calculated with Spearman-rank testCC BY · PubMed Central
Fig. 2 Post-acute mRNA expression of key modulators of iron homeostases and monocyte-derived cytokines in peripheral blood mononuclear cells of COVID-19 patients. Relative ΔΔCT mRNA expression as compared to levels in patients with mild to moderate COVID-19 are shown. Disease severity was categorized according to the need of medical treatment: mild to moderate, outward treatment or inward treatment without respiratory support; severe to critical, inward treatment with the need for respiratory support (oxygen supply or mechanical ventilation). p values depict significant differences between severity groups as calculated with Mann–Whitney U test, error bars indicate 1 standard error; N = 109. TFR1 transferrin receptor 1, DMT1 divalent metal transporter 1, FPN1 ferroportin-1, IL6 interleukin 6, IL10 interleukin 10, TNF tumor necrosis factor, HAMP hepcidin antimicrobial peptide, n.s. not significant
Fig. 2 Post-acute mRNA expression of key modulators of iron homeostases and monocyte-derived cytokines in peripheral blood mononuclear cells of COVID-19 patients. Relative ΔΔCT mRNA expression as compared to levels in patients with mild to moderate COVID-19 are shown. Disease severity was categorized according to the need of medical treatment: mild to moderate, outward treatment or inward treatment without respiratory support; severe to critical, inward treatment with the need for respiratory support (oxygen supply or mechanical ventilation). p values depict significant differences between severity groups as calculated with Mann–Whitney U test, error bars indicate 1 standard error; N = 109. TFR1 transferrin receptor 1, DMT1 divalent metal transporter 1, FPN1 ferroportin-1, IL6 interleukin 6, IL10 interleukin 10, TNF tumor necrosis factor, HAMP hepcidin antimicrobial peptide, n.s. not significantCC BY · PubMed Central
Fig. 3 Association of post-acute hyperferritinemia with COVID-19 severity. a Serum concentrations of ferritin according to disease severity (mild: outward treatment; N = 22; moderate: inward treatment without respiratory support, N = 34; sever: inward treatment with additional respiratory support or intensive care unit admission, N = 53). b Frequency of lung pathologies detected with computed tomography (CT) scan 60 days after disease onset in patients with (N = 41) or without (N = 68) hyperferritinemia. c The severity of pathological CT findings according to the evaluation by two independent experts. The severity of lung involvement detected by CT was graded for each lung lobe and a sum score for the total lung was calculated (0–25 points). N = 109. d Six-minute walking distance in patients with (N = 12) or without (N = 11) hyperferritinemia. p values are reported according to the Kruskal–Wallis test (a) or the Mann–Whitney U test (c, d)
Fig. 3 Association of post-acute hyperferritinemia with COVID-19 severity. a Serum concentrations of ferritin according to disease severity (mild: outward treatment; N = 22; moderate: inward treatment without respiratory support, N = 34; sever: inward treatment with additional respiratory support or intensive care unit admission, N = 53). b Frequency of lung pathologies detected with computed tomography (CT) scan 60 days after disease onset in patients with (N = 41) or without (N = 68) hyperferritinemia. c The severity of pathological CT findings according to the evaluation by two independent experts. The severity of lung involvement detected by CT was graded for each lung lobe and a sum score for the total lung was calculated (0–25 points). N = 109. d Six-minute walking distance in patients with (N = 12) or without (N = 11) hyperferritinemia. p values are reported according to the Kruskal–Wallis test (a) or the Mann–Whitney U test (c, d)CC BY · PubMed Central
Fig. 4 Representative CT scans of COVID-19 patients with or without hyperferritinemia. When comparing lung pathologies in CT scans 60 days after COVID-19 onset, patients with persisting hyperferritinemia presented with significantly more severe lung pathologies. A representative CT scan of two individuals without (a) and with (b) hyperferritinemia are shown
Fig. 4 Representative CT scans of COVID-19 patients with or without hyperferritinemia. When comparing lung pathologies in CT scans 60 days after COVID-19 onset, patients with persisting hyperferritinemia presented with significantly more severe lung pathologies. A representative CT scan of two individuals without (a) and with (b) hyperferritinemia are shownCC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 1 Not valid · 11 Not checked · 34 Own results and interpretations

27 more claims

Create a free account to see all 55 claims and to verify the 24 references still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

See all 197

Metadata

Authors
Sonnweber, T., Boehm, A., Sahanic, S., Pizzini, A., Aichner, M., Sonnweber, B., Kurz, K., Koppelstätter, S., Haschka, D., Petzer, V., Hilbe, R., Theurl, M., Lehner, D., Nairz, M., Puchner, B., Luger, A., Schwabl, C., Bellmann-Weiler, R., Wöll, E., Widmann, G., Tancevski, I., Judith-Löffler-Ragg, & Weiss, G.
Affiliations
  • Innsbruck Medical University (AT)
  • Reha Zentrum Münster Betriebs GmbH (AT)
Corresponding author
Weiss, Günter
Venue
Respiratory Research
Published
2020-10-21
Volume
21
Issue
1
Pages
276-276
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W3094405947
Cited by
177
References
35
Citations by year
2026: 7 · 2025: 11 · 2024: 25 · 2023: 31 · 2022: 57 · 2021: 45 · 2020: 1
FWCI
4.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Respiratory Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Oesterreichische Nationalbank (Project 17271)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
Keywords
COVID-19 pandemic, iron homeostasis, hyperferritinemia, iron deficiency, anemia of chronic disease, long COVID, interleukin-6, C-reactive protein, peripheral blood mononuclear cells, cytokine mRNA expression, physical performance, hyperinflammation
MeSH terms
COVID-19, Adult, Aged, Anemia, C-Reactive Protein, Female, Ferritins, Follow-Up Studies, Homeostasis, Humans, Inflammation, Iron, Lung Diseases, Male, Middle Aged, Monocytes, Pneumonia, Viral, Prospective Studies, Tomography, X-Ray Computed, Cohort Studies, Interleukin-6, Coronavirus Infections, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.